Health economics

¶ 1 Leave a comment on paragraph 1 0 [et_pb_section admin_label=”Seksjon” fullwidth=”on” specialty=”off”][et_pb_fullwidth_post_title admin_label=”Fullbreddes innleggstittel” title=”on” meta=”off” author=”on” date=”on” categories=”on” comments=”on” featured_image=”on” featured_placement=”background” parallax_effect=”off” parallax_method=”on” text_orientation=”right” text_color=”light” text_background=”on” text_bg_color=”rgba(21,150,137,0.9)” module_bg_color=”rgba(255,255,255,0)” title_font=”|on|||” title_font_size=”35px” title_all_caps=”off” use_border_color=”off” border_color=”#ffffff” border_style=”solid” module_id=”header-image-and-text”]

¶ 2 Leave a comment on paragraph 2 0  

¶ 3 Leave a comment on paragraph 3 0 [/et_pb_fullwidth_post_title][/et_pb_section][et_pb_section admin_label=”Seksjon” fullwidth=”off” specialty=”off”][et_pb_row admin_label=”Rad”][et_pb_column type=”2_3″][et_pb_text admin_label=”Tekst” background_layout=”light” text_orientation=”left” use_border_color=”off” border_color=”#ffffff” border_style=”solid”]

Health economics is focused on the allocation of limited resources in the health sector, so that one can achieve both a fair distribution while maximizing health.

¶ 5 Leave a comment on paragraph 5 0 Our research on cancer genomics aims to answer two important research questions:

¶ 6 Leave a comment on paragraph 6 0 1) Is individualized cancer treatment based on genetic testing cost effective by Norwegian guidelines?

¶ 7 Leave a comment on paragraph 7 0 2) How does society value the benefits one gets from individualized treatment based on genetic testing in relation to other types of diagnostics and treatment for cancer?

¶ 8 Leave a comment on paragraph 8 0 The project team consists of researchers from the Department of Health Management and Health Economics, at the University of Oslo, and the research groups for Translational Cancer Genomics and Cancer Treatment at OUS.

¶ 9 Leave a comment on paragraph 9 0 The group is currently working on a health economic model for late stage lung cancer (stage IIIb / IV adenocarcinoma). This is an area where mutation testing and individualized treatment based on mutation status is already applicable in Norway.

¶ 10 Leave a comment on paragraph 10 0 The model will be based on Norwegian clinical practice. Currently, patients are first tested for one mutation (EGFR+) and subsequently for other mutations if the test for EGFR is negative.  Recent advances make it possible to test for multiple mutations simultaneously, which can provide patients and physicians with responses earlier in the diagnosis phase. This could save time and possibly costs. The model provides an opportunity to assess both the costs and consequences for patients associated with the different methods used in Norway.

¶ 11 Leave a comment on paragraph 11 0 In the next stage of the project we will examine the population’s preferences related to cancer genomics and individualized treatment, so that we can assess how these types of measures are valued compared to other types of health improvements.

¶ 12 Leave a comment on paragraph 12 0 [/et_pb_text][/et_pb_column][et_pb_column type=”1_3″][et_pb_sidebar admin_label=”Nyhetsarkiv og konferanser” orientation=”left” area=”primary” background_layout=”light” remove_border=”off”] [/et_pb_sidebar][/et_pb_column][/et_pb_row][/et_pb_section]